Literature DB >> 24114789

High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

Mohammad A Alsenaidy1, Jae Hyun Kim, Ranajoy Majumdar, David D Weis, Sangeeta B Joshi, Thomas J Tolbert, C Russell Middaugh, David B Volkin.   

Abstract

The structural integrity and conformational stability of an IgG1 monoclonal antibody (mAb), after partial or complete enzymatic removal of the N-linked Fc glycan, were compared with the untreated mAb over a wide range of temperature (10°C-90°C) and solution pH (3-8) using circular dichroism, fluorescence spectroscopy, and static light scattering combined with data visualization employing empirical phase diagrams. Subtle-to-larger stability differences between the different glycoforms were observed. Improved detection of physical stability differences was then demonstrated over narrower pH range (4.0-6.0) using smaller temperature increments, especially when combined with an alternative data visualization method (radar plots). Differential scanning calorimetry and differential scanning fluorimetry were then utilized and also showed an improved ability to detect differences in the physical stability of a mAb glycoform. On the basis of these results, a two-step methodology was used in which conformational stability of a mAb glycoform is first screened with a wide variety of instruments and environmental stresses, followed by a second evaluation with optimally sensitive experimental conditions, analytical techniques, and data visualization methods. With this approach, a high-throughput biophysical analysis to assess relatively subtle conformational stability differences in protein glycoforms is demonstrated.
© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  biophysical; conformation; formulation; glycosylation; monoclonal antibody; stability; structure

Mesh:

Substances:

Year:  2013        PMID: 24114789      PMCID: PMC3832129          DOI: 10.1002/jps.23730

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  59 in total

1.  An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1.

Authors:  Mohammad A Alsenaidy; Tingting Wang; Jae Hyun Kim; Sangeeta B Joshi; Jihun Lee; Michael Blaber; David B Volkin; C Russell Middaugh
Journal:  Protein Sci       Date:  2012-02-06       Impact factor: 6.725

2.  Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.

Authors:  Ramil F Latypov; Sabine Hogan; Hollis Lau; Himanshu Gadgil; Dingjiang Liu
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

3.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

4.  Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.

Authors:  Akhilesh Bhambhani; Julian M Kissmann; Sangeeta B Joshi; David B Volkin; Ramesh S Kashi; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2011-12-06       Impact factor: 3.534

5.  Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements.

Authors:  Weiqiang Cheng; Sangeeta B Joshi; Feng He; David N Brems; Bing He; Bruce A Kerwin; David B Volkin; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2012-02-09       Impact factor: 3.534

6.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

Authors:  Martin Schiestl; Thomas Stangler; Claudia Torella; Tadej Cepeljnik; Hansjörg Toll; Roger Grau
Journal:  Nat Biotechnol       Date:  2011-04       Impact factor: 54.908

7.  Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.

Authors:  Sha Ha; Yangsi Ou; Josef Vlasak; Yuan Li; Shiyi Wang; Kim Vo; Yi Du; Anna Mach; Yulin Fang; Ningyan Zhang
Journal:  Glycobiology       Date:  2011-04-05       Impact factor: 4.313

8.  Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.

Authors:  Liming Liu; Andy Stadheim; Lora Hamuro; Tamara Pittman; Weirong Wang; Dongxing Zha; Jerome Hochman; Thomayant Prueksaritanont
Journal:  Biologicals       Date:  2011-07-01       Impact factor: 1.856

Review 9.  The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs.

Authors:  Roy Jefferis
Journal:  Biotechnol Genet Eng Rev       Date:  2010

Review 10.  Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris.

Authors:  Sha Ha; Yang Wang; Richard R Rustandi
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

View more
  9 in total

1.  Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.

Authors:  Ranajoy Majumdar; Reza Esfandiary; Steven M Bishop; Hardeep S Samra; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation.

Authors:  Erik Sedlák; Jonas V Schaefer; Jozef Marek; Peter Gimeson; Andreas Plückthun
Journal:  Protein Sci       Date:  2015-06-11       Impact factor: 6.725

3.  Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.

Authors:  Solomon Z Okbazghi; Apurva S More; Derek R White; Shaofeng Duan; Ishan S Shah; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; Thomas J Tolbert
Journal:  J Pharm Sci       Date:  2016-01-09       Impact factor: 3.534

4.  Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.

Authors:  Pernille Foged Jensen; Vincent Larraillet; Tilman Schlothauer; Hubert Kettenberger; Maximiliane Hilger; Kasper D Rand
Journal:  Mol Cell Proteomics       Date:  2014-11-06       Impact factor: 5.911

5.  Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.

Authors:  Mohammad A Alsenaidy; Solomon Z Okbazghi; Jae Hyun Kim; Sangeeta B Joshi; C Russell Middaugh; Thomas J Tolbert; David B Volkin
Journal:  J Pharm Sci       Date:  2014-04-16       Impact factor: 3.534

Review 6.  Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles.

Authors:  Mohammad A Alsenaidy; Nishant K Jain; Jae H Kim; C Russell Middaugh; David B Volkin
Journal:  Front Pharmacol       Date:  2014-03-12       Impact factor: 5.810

Review 7.  Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life.

Authors:  Abhishek Saxena; Donghui Wu
Journal:  Front Immunol       Date:  2016-12-12       Impact factor: 7.561

8.  CH2 domain orientation of human immunoglobulin G in solution: Structural comparison of glycosylated and aglycosylated Fc regions using small-angle X-ray scattering.

Authors:  Seiki Yageta; Hiroshi Imamura; Risa Shibuya; Shinya Honda
Journal:  MAbs       Date:  2018-12-12       Impact factor: 5.857

Review 9.  Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.

Authors:  Md Harunur Rashid
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.